» Authors » Samy Egli

Samy Egli

Explore the profile of Samy Egli including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 14
Citations 78
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Kopf-Beck J, Muller C, Tamm J, Fietz J, Rek N, Just L, et al.
Psychother Psychosom . 2024 Jan; 93(1):24-35. PMID: 38176391
Introduction: Schema therapy (ST) reduces depressive symptoms, but clinical trials have not investigated its effectiveness for patients suffering from severe forms of depression and high rates of comorbidities. There is...
2.
Gussmann E, Lindner C, Lucae S, Falkai P, Padberg F, Egli S, et al.
Eur Arch Psychiatry Clin Neurosci . 2023 Sep; 274(4):963-979. PMID: 37741946
Emerging evidence suggests the usefulness of psychological interventions targeting metacognitive change mechanisms in patients experiencing psychosis. Although many of these patients are treated in acute psychiatric contexts, only few studies...
3.
Gussmann E, Lucae S, Falkai P, Padberg F, Egli S, Kopf-Beck J
Front Psychiatry . 2023 Jun; 14:1160075. PMID: 37324820
Background: Treatment guidelines for psychosis recommend offering psychotherapy already in the acute illness phase. However, there is a lack of available interventions adapted to the specific needs and key change...
4.
Rek K, Kappelmann N, Zimmermann J, Rein M, Egli S, Kopf-Beck J
Psychol Med . 2022 May; 53(10):4405-4414. PMID: 35534456
Background: Advancements in the treatment of depression are pivotal due to high levels of non-response and relapse. This study evaluated the role of personality pathology in the treatment of depression...
5.
Kopf-Beck J, Zimmermann P, Egli S, Rein M, Kappelmann N, Fietz J, et al.
BMC Psychiatry . 2020 Oct; 20(1):506. PMID: 33054737
Background: Major depressive disorder represents (MDD) a major cause of disability and disease burden. Beside antidepressant medication, psychotherapy is a key approach of treatment. Schema therapy has been shown to...
6.
Kelleher J, Centorrino F, Huxley N, Bates J, Drake J, Egli S, et al.
Eur Neuropsychopharmacol . 2011 Dec; 22(6):415-8. PMID: 22153972
The preferential dopamine D(3)-agonist pramipexole (4.25±0.38 mg/day) or placebo were added for up to 12 weeks to ongoing antipsychotic treatment for 24 adult patients with DSM-IV schizophrenia or schizoaffective disorder....
7.
Lage D, Egli S, Riedel M, Moller H
Eur Arch Psychiatry Clin Neurosci . 2011 Nov; 262(3):227-38. PMID: 22065176
This paper investigates the structure of psychopathological symptoms. Based on AMDP symptom profiles, a symptom space was calculated by robust nonmetric multidimensional scaling (NMDS) and the symptom structures of a...
8.
Lage D, Egli S, Riedel M, Strauss A, Moller H
Eur Arch Psychiatry Clin Neurosci . 2010 Aug; 261(1):3-10. PMID: 20676665
We introduce a diagnostic map that was calculated by robust non-metric multidimensional scaling based on AMDP symptom profiles of patients with schizophrenic and affective disorders to demonstrate a possibility to...
9.
Egli S, Riedel M, Moller H, Strauss A, Lage D
Eur Arch Psychiatry Clin Neurosci . 2009 Jan; 259(3):164-71. PMID: 19165526
Background: In the current debate about the categorical or dimensional classification of mental disorders many fruitful methods to illustrate one or the other aspect are employed, and suggestions are made...
10.
Egli S, Streule R, Lage D
Psychopathology . 2008 Jul; 41(5):286-93. PMID: 18594163
Background: In an earlier study, our research group presented an alternative approach to measuring knowledge about mental disorders by constructing a structure-based expert model of the ICD-10 mental disorders. This...